Evommune (EVMN) Operating Income (2024 - 2026)

Evommune (EVMN) has 3 years of Operating Income data on file, last reported at -$24.0 million in Q1 2026.

• On a quarterly basis, Operating Income fell 59.35% year-over-year to -$24.0 million in Q1 2026; TTM through Mar 2026 was -$82.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$81.1 million, down 15.79% from the prior year.
• Operating Income for Q1 2026 stood at -$24.0 million, up from -$29.7 million in the prior quarter.
• Over the last five years, Operating Income for EVMN reached as high as -$13.3 million in Q3 2025 and fell as low as -$29.7 million in Q4 2025.
• Historically, Operating Income has averaged -$20.0 million across 3 years, with a median of -$19.0 million in 2024.
• Across the five-year window, Operating Income gained 19.31% in 2025 and slumped 59.35% in 2026, its largest moves.
• Year by year, Operating Income stood at -$21.5 million in 2024, then plunged by 38.51% to -$29.7 million in 2025, then grew by 19.39% to -$24.0 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$24.0 million in Q1 2026, -$29.7 million in Q4 2025, and -$13.3 million in Q3 2025.